IN8bio, Inc

IN8bio, Inc is a leading clinical-stage biopharmaceutical company based in New York, NY, specializing in the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. Their innovative approach employs various techniques, including allogeneic, autologous, iPSC, and genetically modified approaches, to develop novel cell therapies that effectively identify and eradicate tumor cells.

With a mission to achieve "CANCER ZERO," IN8bio is at the forefront of gamma-delta T cell research and was the first to bring genetically modified gamma-delta T cells into clinical trials. Their DeltEx platform technologies harness the unique properties of gamma-delta T cells, enabling them to differentiate between healthy and diseased tissue, and contribute to direct tumor cell killing and immune cell activation. With a dedicated team of experts and a robust pipeline of clinical and preclinical assets, IN8bio is committed to advancing next-generation cancer treatments for patients in need.

Generated from the website